These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32817705)

  • 21. [Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities].
    Thomsen BL; Herz DM; Siebner HR; Løkkegaard A
    Ugeskr Laeger; 2017 Mar; 179(10):. PubMed ID: 28263159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.
    Hong JY; Oh JS; Lee I; Sunwoo MK; Ham JH; Lee JE; Sohn YH; Kim JS; Lee PH
    Neurology; 2014 May; 82(18):1597-604. PubMed ID: 24719485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD.
    Yoo HS; Chung SJ; Lee YH; Lee HS; Ye BS; Sohn YH; Lee PH
    Neurology; 2019 Mar; 92(13):e1468-e1478. PubMed ID: 30796137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson's disease.
    Yoo HS; Lee EC; Chung SJ; Ye BS; Sohn YH; Seong JK; Lee PH
    Sci Rep; 2022 Jul; 12(1):12631. PubMed ID: 35879381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson's disease patients.
    Dias CMV; Leal DAB; Brys I
    Int J Neurosci; 2023 Dec; 133(12):1319-1325. PubMed ID: 35603453
    [No Abstract]   [Full Text] [Related]  

  • 26. A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.
    Simon N; Viallet F; Boulamery A; Eusebio A; Gayraud D; Azulay JP
    Eur J Clin Pharmacol; 2016 Apr; 72(4):423-30. PubMed ID: 26936272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease.
    Wang CC; Wu TL; Lin FJ; Tai CH; Lin CH; Wu RM
    Eur J Neurol; 2022 Apr; 29(4):1044-1055. PubMed ID: 34962701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex-specific association of urate and levodopa-induced dyskinesia in Parkinson's disease.
    Jung JH; Chung SJ; Yoo HS; Lee YH; Baik K; Ye BS; Sohn YH; Lee PH
    Eur J Neurol; 2020 Oct; 27(10):1948-1956. PubMed ID: 32441832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
    Nicoletti A; Mostile G; Nicoletti G; Arabia G; Iliceto G; Lamberti P; Marconi R; Morgante L; Barone P; Quattrone A; Zappia M
    J Neurol; 2016 May; 263(5):888-894. PubMed ID: 26964541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
    Chaudhuri KR; Jenner P; Antonini A
    Mov Disord; 2019 Jun; 34(6):816-819. PubMed ID: 30983023
    [No Abstract]   [Full Text] [Related]  

  • 31. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia.
    Kipfer S; Stephan MA; Schüpbach WM; Ballinari P; Kaelin-Lang A
    Arch Neurol; 2011 Aug; 68(8):1037-9. PubMed ID: 21825240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.
    Li MH; Mestre TA; Fox SH; Taati B
    J Neuroeng Rehabil; 2018 Nov; 15(1):97. PubMed ID: 30400914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications.
    Kostić VS; Marinković J; Svetel M; Stefanova E; Przedborski S
    Eur J Neurol; 2002 Jan; 9(1):9-14. PubMed ID: 11784369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study.
    Santos-García D; de Deus T; Cores C; Feal Painceiras MJ; Íñiguez Alvarado MC; Samaniego LB; López Maside A; Jesús S; Cosgaya M; García Caldentey J; Caballol N; Legarda I; Hernández-Vara J; Cabo López I; López Manzanares L; González-Aramburu I; Ávila A; Gómez-Mayordomo V; Nogueira V; Dotor García-Soto J; Borrué-Fernández C; Solano B; Álvarez Sauco M; Vela L; Escalante S; Cubo E; Mendoza Z; Pareés I; Sánchez Alonso P; Alonso Losada MG; López-Ariztegui N; Gastón I; Kulisevsky J; Seijo M; Valero C; Alonso Redondo R; Buongiorno MT; Ordás C; Menéndez-González M; McAfee D; Martinez-Martin P; Mir P;
    Mov Disord Clin Pract; 2024 Jul; 11(7):830-849. PubMed ID: 38747234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
    Thanvi B; Lo N; Robinson T
    Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction.
    Russmann H; Ghika J; Combrement P; Villemure JG; Bogousslavsky J; Burkhard PR; Vingerhoets FJ
    Neurology; 2004 Jul; 63(1):153-5. PubMed ID: 15249627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

  • 38. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).
    Sharma JC; Macnamara L; Hasoon M; Vassallo M; Ross I
    Parkinsonism Relat Disord; 2006 Dec; 12(8):499-505. PubMed ID: 16935018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.